Abstract
Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 559-569 |
| Number of pages | 11 |
| Journal | Bone Marrow Transplantation |
| Volume | 44 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2009 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation : Another autograft or switch to allograft? / Freytes, C. O.; Lazarus, H. M.
In: Bone Marrow Transplantation, Vol. 44, No. 9, 2009, p. 559-569.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation
T2 - Another autograft or switch to allograft?
AU - Freytes, C. O.
AU - Lazarus, H. M.
PY - 2009
Y1 - 2009
N2 - Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.
AB - Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.
UR - http://www.scopus.com/inward/record.url?scp=70749090444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70749090444&partnerID=8YFLogxK
U2 - 10.1038/bmt.2009.214
DO - 10.1038/bmt.2009.214
M3 - Article
VL - 44
SP - 559
EP - 569
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 9
ER -